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Much evidence suggests a protective role of high-density lipoprotein (HDL) and its major
apolipoprotein apoA-I, in Alzheimer’s disease (AD). The biogenesis of nascent HDL
derived from a first lipidation of apoA-I, which is synthesized by the liver and intestine
but not in the brain, in a process mediated by ABCA1. The maturation of nascent HDL in
mature spherical HDL is due to a subsequent lipidation step, LCAT-mediated cholesterol
esterification, and the change of apoA-I conformation. Therefore, different subclasses of
apoA-I-HDL simultaneously exist in the blood circulation. Here, we investigated if and
how the lipidation state affects the ability of apoA-I-HDL to target and modulate the
cerebral β-amyloid (Aβ) content from the periphery, that is thus far unclear. In particular,
different subclasses of HDL, each with different apoA-I lipidation state, were purified
from human plasma and their ability to cross the blood-brain barrier (BBB), to interact
with Aβ aggregates, and to affect Aβ efflux across the BBB was assessed in vitro using a
transwell system. The results showed that discoidal HDL displayed a superior capability
to promote Aβ efflux in vitro (9 × 10−5 cm/min), when compared to apoA-I in other
lipidation states. In particular, no effect on Aβ efflux was detected when apoA-I was in
mature spherical HDL, suggesting that apoA-I conformation, and lipidation could play a
role in Aβ clearance from the brain. Finally, when apoA-I folded its structure in discoidal
HDL, rather than in spherical ones, it was able to cross the BBB in vitro and strongly
destabilize the conformation of Aβ fibrils by decreasing the order of the fibril structure
(−24%) and the β-sheet content (−14%). These data suggest that the extent of apoA-I
lipidation, and consequently its conformation, may represent crucial features that could
exert their protective role in AD pathogenesis.
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INTRODUCTION
Apolipoprotein A-I (apoA-I) is involved in the generation and
metabolism of high-density lipoproteins (HDL) (Zannis et al.,
2006). The 28 kDa protein is synthesized in the small intestine
and liver, and lipidated with cholesterol and phospholipids
by the membrane-bound ATP-binding cassette transporter A1
(ABCA1) to create different subclasses of plasma HDL particles,
including discoidal ones. Subsequently, a second lipidation step,
mediated by LCAT, is required for maturation of nascent HDL
into mature spherical lipid-rich HDL (Oram and Heinecke,
2005; Curtiss et al., 2006). During the HDL maturation process
the secondary structure of apoA-I slightly changes (Sevugan
Chetty et al., 2012). Therefore, in humans, HDL consist of
heterogeneous subclasses, characterized according to charge, size,
density, protein, and/or lipid composition. HDL are involved
in removing excess cholesterol from peripheral tissues, e.g., the
arterial wall, and transporting it to the liver for secretion by
reverse cholesterol transport. HDL exert other protective effects,
including anti-oxidative, anti-inflammatory, anti-apoptotic, and
anti-infective actions (Kingwell et al., 2014).
It is well established that plasma levels of HDL cholesterol
(HDL-c) and apoA-I, the major protein component of plasma
HDL, inversely correlate with the development of many
disorders, including cardiovascular diseases, diabetes, obesity,
cancer, and infectious diseases. Dysregulated HDL metabolism
has also been linked to brain disorders: a decrease in plasma levels
of HDL-c and/or apoA-I are risk factors for memory decline
and neurodegenerative diseases, such as Alzheimer’s disease (AD)
(Vitali et al., 2014).
Alzheimer’s disease is the most common type of dementia
and affects tens of millions of people worldwide. The amyloid
hypothesis (Haass and Selkoe, 1993; Glenner and Wong, 2012;
Selkoe and Hardy, 2016) proposes that β-amyloid peptide (Aβ),
the main component of senile plaques, is the key player in
AD pathogenesis. Aβ monomers, derived from the proteolytic
cleavage of the larger glycoprotein amyloid precursor protein, if
not efficiently cleared from the brain can aggregate into different
assemblies, which can then form regular fibrils and plaques.
Some evidence suggests that apoA-I might be involved in the
pathogenesis of AD, but its role has not yet been elucidated.
In a recent publication, Robert et al. (2017a) suggest that the
risk to develop AD could be reduced when supported by high
concentrations of plasma levels of HDL and apoA-I. It has also
been shown that higher plasma levels of HDL and apoA-I are
directly correlated with an increased MMSE and a lower risk of
developing AD (Merched et al., 2000). Moreover, a reduction of
hippocampal and whole brain volume and of cortical thickness
has been detected in AD patients, along with lower plasma
levels of apoA-I (Hye et al., 2014). In another study, reduced
serum apoA-I has been detected in AD, contrarily to non-
demented age-matched patients (Shih et al., 2014). This body of
evidence suggests that apoA-I could play a protective role in AD
pathogenesis, possibly by promoting the clearance of Abeta from
the brain. In favor of this hypothesis are also in vivo studies on AD
mouse animal models, showing that cognitive deficit is prevented
by apoA-I overexpression (Lewis et al., 2010), while it is worsened
by its deletion (Lefterov et al., 2010), and i.v., administration of
HDL reduces soluble Aβ brain levels (Robert et al., 2016).
However, more research is needed to clarify its implications
and no information is available concerning the possible role of
distinct HDL subclasses. In this study, we investigate in vitro the
ability of apoA-I in different lipidation states to affect Aβ eﬄux
across the BBB, using a transwell system made by immortalized
human brain capillary endothelial cells.
Moreover, it is known that apoA-I is present in the brain
(Elliott et al., 2010), but its mRNA has not been detected (Mahley
et al., 1984; Harr et al., 1996; Huang et al., 2008). Thus, brain
apoA-I is believed to be plasma derived from peripheral HDL that
cross the blood-brain barrier (BBB) (Roheim et al., 1979; Pitas
et al., 1987; Stukas et al., 2014; Fung et al., 2017).
Therefore, within the present study we have also investigated
how the extent of apoA-I lipidation (giving rise to different HDL
subclasses) affects the traversing of the BBB and the interaction
with Aβ aggregates; an issue that, to the best of our knowledge,
has never been investigated before.
MATERIALS AND METHODS
Human Samples
Human plasma samples from healthy donors were provided
by the Immunohematology and Transfusion Medicine Service
(SIMT) of ASST Grande Ospedale Metropolitano Niguarda,
Milan. All experimental protocols were approved by license 446-
092014 CE from Ospedale Niguarda Ca’ Granda and carried out
in accordance with these guidelines and regulations. Informed
consent was obtained from all donors. Plasma was prepared by
low speed centrifugation at 4◦C and lipoprotein isolation started
within 6 h of blood collection.
Purification of apoA-I-HDL From
Human Plasma
High-density lipoprotein (d = 1.063–1.21 g/mL) were purified
from human plasma of healthy blood donors by sequential
ultracentrifugation. Purified lipoproteins were dialyzed against
saline immediately before use and were representative of the
total HDL pool of human plasma. This sample was treated
with chymase, which degrades small discoidal HDL particles,
to obtain a fraction containing only spherical apoA-I-HDL
(Favari et al., 2004). Briefly, apoA-I-HDL plasma pool was
incubated with granule remnants isolated from rat mast cells
(30◦µg/ml of granule remnant total protein, equal to 40
BTEE Units/ml) for 2 h at 37◦C. After incubation, tubes
were placed on ice and centrifuged at 4◦C, 12,000 rpm,
for 5 min to remove the granule remnant-bound chymase,
and the chymase-free supernatants were collected. The lack
of discoidal, apoA-I-containing HDL was verified by non-
denaturing two-dimensional (2-D) electrophoresis, in which
agarose gel electrophoresis was followed by non-denaturing
gradient gel electrophoresis (GGE), and immunoblotting against
apoA-I. Spherical apoA-I-HDL were characterized by AFM, as
described below.
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Preparation of Discoidal HDL
Apolipoprotein A-I was purified from human plasma by
gel-filtration chromatography (Bernini et al., 1996) and
its purity (>95%) was confirmed by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) using Coomassie protein
staining, as previously described (Schägger and von Jagow,
1987). This sample represents lipid-poor apoA-I, having few
bound phospholipid molecules. Discoidal apoA-I-HDL were
prepared by the cholate dialysis method using palmitoyl-
oleoyl-phosphatidylcholine (POPC) and apoA-I in the
weight ratio of 2.5:1 (Calabresi et al., 1997). Their size was
estimated by non-denaturing GGE using precast 4–30% gels
and the Pharmacia Phast System (Franceschini et al., 2013).
Phospholipid content of lipid-poor apoA-I and discoidal
HDL was measured by an enzymatic method and apoA-I
concentration was measured by Lowry method. The final
preparation of discoidal HDL contained 2 apoA-I and 205
POPC molecules. Discoidal HDL were characterized by AFM, as
described below.
Atomic Force Microscopy Imaging of
apoA-I-HDL
Atomic force microscopy (AFM) imaging was performed using
a Nanowizard II (JPK Instruments, Berlin) scanning probe
microscope operating in tapping and contact mode in air. In
tapping mode imaging of Aβ1−42 fibrils, RTESP-300 (Bruker,
United States) cantilevers were used with a nominal force
constant of 40 N/m, a resonance frequency of 300 kHz, and
a nominal tip radius 8 nm. For contact mode imaging of
HDL subtypes, DNPS-10 (Bruker, United States) cantilevers
were used with a nominal force constant of 0.06 N/m, and
a nominal tip radius 10 nm. A detailed protocol used for
the apoA-I-HDL characterization is supplied as Supplementary
Information (see section “Characterization of HDL by AFM
Imaging”). A wide range of areas of AFM images were
analyzed using the commercial JPK image processing software
and a customized image-analysis software (Matlab, MathWorks
Inc, United States).
Preparation and Characterization of
Aβ Aggregates
Aβ1−42 (Sigma–Aldrich, Milan, Italy) fibrils were prepared as
described (Gregori et al., 2010; Bana et al., 2014; Mancini
et al., 2016). Briefly, the peptide (1 mg/mL) was solubilized in
1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma–Aldrich, Milan,
Italy), dried, resuspended in DMSO at a concentration of
5 mM, and bath sonicated for 10 min. To obtain a fibril-
enriched preparation, samples were diluted to 200µM in
10 mM HCl and incubated at 37◦C for 72 h. Aβ fibrils
were characterized by AFM (Gregori et al., 2010). For the
fibrillation process, samples were diluted to 100µM in 10 mM
HCl and incubated at 37◦C. In the reported images, Aβ was
diluted to a final concentration of 10◦µM in 10 mM HCl and
deposited on freshly cleaved mica. Images were acquired in air
in tapping mode.
Preparation and Characterization of the
in vitro Model of Blood-Brain Barrier
The in vitro BBB model was prepared and characterized
as previously described (Mancini et al., 2016), using
immortalized human brain endothelial cells (hCMEC/D3
cells) from Institut National de la Sante et de la Recherche
Medicale, Paris, France. Briefly, hCMEC/D3 were seeded
(60,000 cells/cm2) onto collagen-coated (8◦µg/cm2 rat
tail collagen type 1; Gibco, Thermo Fisher Scientific)
transwell filters (polycarbonate 12-well, pore size 0.4◦µm,
translucent membrane inserts 1.12 cm2; Costar) to establish
a polarized monolayer. The cell monolayer separates two
compartments, an apical one (0.5 ml) representing the
blood and a basolateral one (1 ml) representing the brain.
Cells were grown for 3 days in complete EBM-2 medium
(1.4◦µM hydrocortisone, 10 mM HEPES, 1% penicillin-
streptomycin, 5◦µg.mL−1 ascorbic acid, and 1% chemically
defined lipid concentrate) supplemented with 1 ng.mL−1
basic fibroblast growth factor and 10% fetal bovine serum
(FBS). After 3 days in vitro (DIV), medium was changed
to complete EBM-2 medium supplemented with 5% FBS,
and 10 mM LiCl and grown for a further 3 days. Trans-
endothelial electrical resistance (TEER) was monitored
with STX2 electrode Epithelial Volt-Ohm meter (World
Precision Instruments, Sarasota, FL, United States). The
formation of junctions was evaluated by confocal microscopy
(LSM710, Carl Zeiss, Oberkochen, Germany) and by
measuring the endothelial permeability (EP) to [14C-sucrose]
(0.5◦µCi) and [3H]-propranolol (0.5◦µCi), as described
(Bana et al., 2014). Cell viability was assessed by MTT assay
(Bana et al., 2014).
Effect of apoA-I Lipidation on in vitro Aβ
Efflux Across the BBB
Five hundred nanomolar of Aβ fibrils dissolved in 1 ml
of complete culture medium were placed in the basolateral
compartment of the transwell system, as previously described
(Mancini et al., 2016). The impact of this treatment on the
cell monolayer was evaluated by monitoring TEER, EP to
radiolabeled probes, and cell viability, following the procedure
described above. 5 nmol/ml of apoA-I in discoidal HDL,
spherical HDL, or total HDL plasma pool (Merino-Zamorano
et al., 2016) dissolved in 500◦µl of PBS was added to
the apical compartment of the transwell. The impact on
hCMEC/D3 monolayers of the treatments was determined
by measuring the TEER after 3–24 h of incubation with
apoA-I-HDL in the apical side of transwells. After different
incubation times (up to 3 h) at 37◦C, aliquots from the
apical compartment were collected and the Aβ content was
measured by ELISA assay (IBL International, Italy). The Aβ
EP across the cell monolayer from the basolateral to the
apical compartment (defined as Aβ eﬄux) was calculated
as described (Bana et al., 2014; Mancini et al., 2016).
As controls, 5 nmol/ml of commercially available apoA-I
(Sigma-Aldrich, Milano, Italy) was dissolved in PBS and added
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to the apical compartment. The Aβ eﬄux was determined as
previously described.
Effect of Lipidation of apoA-I on Its
Ability to Cross the BBB in vitro
A total of 5 nmol/ml of apoA-I in discoidal HDL, spherical
HDL, or total HDL plasma pool dissolved in 500◦µl of PBS was
added to the apical compartment of the transwell and incubated
at 37◦C. After different times (up to 3 h) of incubation, the
amount of apoA-I in the basolateral compartment was measured
by ELISA assay (IBL International, Italy), and EP was calculated
as described (Bana et al., 2014; Mancini et al., 2016).
Effect of apoA-I Lipidation on Preformed
Aβ Fibrils
Fifty micromolar Aβ1−42 fibrils were incubated at 37◦C in buffer
B (PBS 15 mM and NaCl 20 mM, pH 7.4) with discoidal
HDL, spherical HDL, or apoA-I-HDL plasma pool, containing
0.18 nmol/ml of apoA-I in order to mimic its low brain
concentration (Roheim et al., 1979; Fagan et al., 2000). After
different times of incubation an aliquot from each sample was
immobilized on a freshly cleaved mica substrate, rinsed with
Milli-Q water, dried under a gentle stream of nitrogen, and
analyzed by AFM.
The effect of apoA-I lipidation on preformed Aβ fibrils
was also monitored by ThT assay (Quan et al., 2016). Briefly,
2◦µM of Aβ fibrils were added with 5◦µM ThT (Sigma-Aldrich,
Milan, Italy), 10 mM glycine buffer pH 8.5 in 1 cm2 × 1 cm2
fluorimeter quartz cuvettes equipped with hermetic tips to
prevent evaporation. 0.0036 nmol/ml of apoA-I in discoidal HDL,
spherical HDL, or total HDL plasma pool were added to the
sample and the ThT fluorescence (ex. 450 nm; em. 485 nm)
was monitored at 37◦C under stirring with a FP8500 fluorimeter
(Jasco) equipped with a 4-cells peltier-thermostated sample
holder. Low Aβ and apoA-I concentrations (25-fold less than in
the AFM experiments) were utilized for ThT experiments since
fibrils produce sizeable scattering of the fluorescence excitation
light, and in order to maintain the Aβ:apoA-I molar ratio as in
the AFM experiments.
Molecular Modeling of apoA-I
The recently obtained discoidal HDL with apoA-I (Bibow et al.,
2017) without helix-5 was considered the starting point for
this work (PDB ID: 2N5E). It was demonstrated by chemical
shift comparison and lipid paramagnetic relaxation enhancement
experiments (Bibow et al., 2017) that apoA-I with and without
helix 5 are structurally similar, strongly indicating that the overall
structure of apoaA-I is preserved in the shortened construct
considered in the present study. One hundred 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC) lipid molecules were
inserted as previously described (Bibow et al., 2017). This model
was solvated and neutralized by adding 0.15 M Na and Cl
ions. CHARMM36 force field (Huang and MacKerell, 2013)
was used to define protein and lipids topologies, and TIP3P
model (Jorgensen et al., 1983) was used for the water molecules.
The obtained system was minimized by applying 1,000 steps
of steepest descent energy minimization algorithm, followed by
preliminary NVT of 200 ps. V-rescale thermostat was applied to
maintain the temperature at 300 K with a time constant of 0.1
ps (Bussi et al., 2007). An NPT of 200 ps was carried out at 300
K (τ = 1 ps) and 1 atm (τ = 5 ps). V-rescale (Bussi et al., 2007)
and Berendsen (Berendsen et al., 1984) coupling methods were
used as temperature and pressure coupling. Finally, molecular
dynamics (MD) equilibration of 100 ns was performed to
optimize the DMPC/apoA-I complex.
Computational Docking and MD of
apoA-I in Complex With Aβ Fibril
To determine the initial orientation of Aβ fibrils on DMPC/apoA-
I complex, a pentamer of Aβ17−42 was extracted from the
PDB model 2BEG (Lührs et al., 2005), and considered for
docking experiments (Yu and Zheng, 2012). In this NMR
model, each peptide monomer has the disordered N-terminal
residues 1–16 missing. However, the remaining residues 17–42
were suggested to contribute the stability of the mature fibril
mostly and were included in the simulation models here, as
described in previous computational studies (Fan et al., 2015;
Grasso et al., 2018). The Aβ17−42 model was first docked on
apoA-I using Patchdock (Schneidman-Duhovny et al., 2005).
The top-scored 100 conformations were subjected to Firedock
(Andrusier et al., 2007; Mashiach et al., 2008) to refine and
rescore docking solutions. The top ranked molecular system
was solvated in a cubic box of 13 nm3× 11 nm3× 8 nm3
and neutralized by counterions. Each system consisted of
approximately 120,000 interacting particles. CHARMM36 force
field (Huang and MacKerell, 2013) was used to define protein
and lipids topologies, while TIP3P model (Jorgensen et al., 1983)
was used for water molecules. The system was first minimized
by applying the steepest descent energy minimization algorithm.
Three different replicas of the same system were generated with
different initial velocities to increase the statistics of MD data.
A preliminary MD simulation of 100 ps was performed in
NPT ensemble at 300 K (τ = 1 ps) and 1 atm (τ = 5 ps) by
applying position restraints on the heavy atoms of the solute.
V-rescale (Bussi et al., 2007) and Berendsen (Berendsen et al.,
1984) coupling methods were used as temperature and pressure
coupling. Finally, three production simulations were performed
at 300K for 100 ns. For comparison, Aβ17−42 alone in water
was also simulated. Principal component analysis (PCA) was
applied to reduce the dimensionality of the system (Deriu et al.,
2016a; Grasso et al., 2016), elucidating large-scale and low-
frequency modes, thus yielding collective motions related to the
destabilization of the Aβ17−42 fibril (Maisuradze et al., 2009).
After the alignment of Aβ17−42 C-α Cartesian coordinates, the
covariance matrix was calculated and diagonalized. To estimate
the structural order of the Aβ17−42 model and to what extent
fibrils chains are aligned, an order parameter was calculated for
each MD snapshot using equation (1):
(1)ordP = 1
Nr
42∑
r=17
〈vr, z〉
‖vr‖ · ‖z‖ =
1
Nr
42∑
r=17
cos α
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where N, is the number of residues along the peptide chain; vr
is the vector joining each of the Cα-atoms pertaining to chain A
with the corresponding Cα-atom (same residue number) of chain
E; and z is the fibril axis. Values of ordP close to 1 indicate the
amyloid-like shape alignment, whereas values of ordP < 1 are
typical of a distorted structure.
Statistical Analysis
Data are expressed as mean ± SEM or SD obtained from
three independent experiments, each of them in triplicate. Data
were analyzed with one-tailed Student’s t test for MD analysis.
Data from in vitro transwell assays were analyzed with one-way
ANOVA and the Tukey’s post hoc test was applied. p-value< 0.05
was considered significant.
RESULTS
Characterization of apoA-I-HDL
Plasma derived HDL were analyzed by 2D-GGE (Figure 1A).
Left smear represents the subclass of discoidal apoA-I-HDL
and right smear represents the subclass of spherical apoA-
I-HDL, as previously described (Didichenko et al., 2016).
About 10–14% of apoA-I-HDL plasma pool is represented by
discoidal apoA-I-HDL. This sample was treated with chymase
in order to selectively degrade discoidal apoA-I-HDL, obtaining
a preparation containing mature spherical apoA-I-HDL. In
Figure 1B, the complete degradation of discoidal particles is
evident, indicated by the disappearance of their smear. Synthetic
discoidal apoA-I-HDL were also characterized by 2D-GGE
(Figure 1C). As expected, the discoidal particles migrate in
FIGURE 1 | Characterization of HDL by 2D-GGE. Total HDL, purified from
human plasma, were separated by two-dimensional electrophoresis and
transferred onto a nitrocellulose membrane, on which different HDL
subclasses were detected by immunoblotting using anti-human apoA-I
antibody. (A) Plasma derived apoA-I-HDL (total plasma HDL). (B) Spherical
apoA-I-HDL, derived from plasma HDL preparation after incubation for 2 h at
37◦C with chymase-containing granule remnants, which degrades small
discoidal HDL particles. (C) Synthetic discoidal apoA-I-HDL, prepared by the
cholate dialysis method.
the pre-beta region. The estimated diameter of HDL by 2D-
GGE is 11 ± 2 nm for spherical HDL and 8.8 ± 0.2 nm for
synthetic discoidal HDL.
Spherical and discoidal apoA-I-HDL were also characterized
by AFM imaging (Supplementary Figure 2). Both HDL
subclasses displayed visual homogeneity in size distribution
and morphology (Figures 2A,B). The height statistical
distributions of AFM imaging allowed discrimination between
the spherical and discoidal shapes (Figure 2C) and showed
that the average dimensions of the two HDL subclasses were
comparable (spherical apoA-I-HDL diameter 2RS 12.7 nm,
discoidal apoA-I-HDL size 12.9 nm). It should be noted
that the HDL sizes obtained by using 2D-GGE and AFM
techniques agree qualitatively, even if there are inherent
technical differences between the two methods, which do not
allow direct comparison of the results.
The extent of apoA-I lipidation, determined by measuring the
phospholipid content, was 92:1 mmol lipids/mmol apoA-I for
synthetic discoidal apoA-I and 15:1 mmol lipids/mmol apoA-I
for lipid-poor apoA-I, as calculated from our own and previously
published data (Jayaraman et al., 2012).
FIGURE 2 | Representative images of the morphology of HDL subclasses
obtained by AFM imaging. (A) Discoidal and (B) spherical HDL on APTES
functionalized mica (4 µm2 × 4 µm2, 1024 × 1024-pixel, Z-scale 20 nm),
with 3-dimensional projections of a 1 µm2 × 1 µm2 region (white squares in
the images). (C) Normalized height statistical distributions of spherical (red)
and discoidal (green) HDL in the range 4–25 nm. The red fit is the theoretical
distribution for a sphere (2RS = 12.7 nm), the green filled area represents the
δ-function (hD = 12.9 nm) and the green dotted line is the linear regression for
the final part of the distribution.
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Characterization of Aβ Fibrillation
The aggregation process of Aβ from monomers to fibrils was
followed and characterized by AFM imaging. Several images were
acquired at the beginning of the fibrillation (t = 0h) and at
successive fixed times (t = 4, 8, 24, and 48 h). Representative
images are illustrated in Figure 3A. The results showed that
long fibrils were formed over time, as previously observed
(Gregori et al., 2010). The aggregation is characterized by
progressive formation of unbranched fibrils of constant diameter
and increasing length.
The process of fibril growth can be quantitatively evaluated
by considering the time evolution of the number of pixels
above a fixed height threshold in the AFM images of fibril
morphology (Supplementary Figures 1, 2). Figure 3B shows
AFM images of Aβ fibrils at different incubation times with a
height threshold of 1.5 nm. The percentage of pixels above a
certain threshold increases with fibril extension and density, and
it can be considered as a quantitative index of the aggregation
process. Threshold pixel percentages over time (Figure 3C) show
that there is continuous Aβ fibril growth in length up to 48 h.
Characterization of in vitro BBB Model
The in vitro BBB model was prepared and characterized
(Figure 4). The TEER was monitored over time and the results
showed that the maximum value (116.37 ± 4.37 /cm2) was
registered 6 days after seeding (Figure 4B). At this time point,
the formation of junctions was checked by confocal microscopy
and by measuring the paracellular and transcellular EP of
radiolabeled sucrose and propranolol, respectively. The results
showed that Claudin-5 (Figure 4C, stained in green) and VE-
Cadherin (Figure 4C, stained in red), two key components
of tight and adherens endothelial junctions, are formed in
FIGURE 3 | Aggregation process of Aβ from monomers to fibrils studied by AFM. Representative images of Aβ at different fibrillation stages (t = 0, 4, 8, 24, and 48 h)
of incubation at 37◦C. (A) AFM images: 4 µm2 × 4 µm2, 1024 × 1024-pixel, Z-scale 10 nm. (B) A fixed height threshold (here 1.5 nm) is applied to the AFM images
in order to quantify the number of pixels above this threshold, expressed in terms of percentage with respect the total number of pixels. The number of such pixels is
proportional to the total length of the fibril i.e., to the sum of the lengths of all the deposited fibrils. In this way, it is possible to quantify the fibril growth.
(C) Quantification of the fibrillation. Percentage of pixel above a height threshold (1.5 nm) as obtained from AFM images, plotted as a function of the incubation time
at 37◦C.
Frontiers in Neuroscience | www.frontiersin.org 6 May 2019 | Volume 13 | Article 419
fnins-13-00419 May 15, 2019 Time: 16:34 # 7
Magro et al. ApoA-I Lipidation and β-Amyloid Clearance
the hCMEC/D3 monolayer 6 days after seeding. The EP of
[3H]-propranolol and [14C]-sucrose was 1.56 ± 0.13 × 10−5
and 3.83 ± 0.84 × 10−5 cm/min, respectively, suggesting
that tight junctions had formed (Figure 4D). At 6 days after
seeding, 500 nM of Aβ fibrils (characterized by AFM images,
see Figure 3) were added to the basolateral compartment
of the transwell system and the impact of fibrils on cell
monolayer properties was checked. After 3h of hCMEC/D3
monolayer exposure to fibrils, TEER did not significantly change
(114.10 ± 4.82  cm2) nor did EP of trans- and para-cellular
probes (Figure 4D). Moreover, the treatment did not affect cell
viability (>95% cells viability with respect to untreated cells), as
assessed by MTT assay.
The impact on hCMEC/D3 monolayers of the
different subclasses of apoA-I-HDL was determined by
measuring the TEER after 3 and 24 h of incubation
with particles in the apical side of transwells. The
results showed that the treatments of cell monolayers
with HDL did not affect their bioelectrical properties,
with TEER values of 114 ± 11 ·cm2 after treatment
(Supplementary Table 1).
Effect of apoA-I Lipidation on in vitro Aβ
Efflux Across the BBB
The Aβ eﬄux from the basolateral compartment of the
transwell when apoA-I in different lipidation states were present
in the apical compartment was measured by ELISA assay
(Supplementary Figure 5).
The presence of apoA-I in the apical compartment
significantly increased Aβ eﬄux from the basolateral side
FIGURE 4 | In vitro BBB model. The in vitro BBB model, made in a transwell system by culturing hCMEC/D3 cells was characterized by monitoring the TEER values
over time, by probing the formation of tight junctions and by measuring the para- and transcellular passage of radioactively labeled probes. (A) Graphical
representation of BBB model. (B) TEER values monitored from 2 to 10 days in culture. (C) confocal microscopy visualization of tight and adherens junctions (blue,
nuclei; green, ZO-1; and red, VE-cadherin). (D) endothelial permeability of [14C]-sucrose, as probe for paracellular permeability, and [3H]-propranolol, as probe for
transcellular permeability, before and after incubation with Aβ fibrils in the basolateral compartment of the transwell system.
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of the BBB model (Figure 5A). In particular, the ability of
apoA-I to enhance the Aβ eﬄux increased with the increase of
its lipidation state, reaching maximum Aβ eﬄux when discoidal
apoA-I-HDL were present in the apical compartment.
The discoidal apoA-I-HDL significantly increased Aβ eﬄux
from the basolateral side of the BBB model, compared to the
apoA-I-HDL plasma pool (p = 0.0016) and spherical apoA-I-HDL
(p = 0.011) (Figure 5B).
FIGURE 5 | Aβ efflux across the BBB model in the presence of human plasma-derived HDL. hCMEC/D3 cells were cultured on a transwell system and 500 nM of Aβ
fibrils was added to the medium in the basolateral compartment. Different subclasses of HDL or Aβ-binding proteins were added to the apical compartment and the
Aβ efflux from the basolateral compartment was measured by ELISA assay. (A) Endothelial permeability (EP) values of Aβ in the presence of lipid-free, lipid-poor or
discoidal apoA-I, and the ratio of lipids to apoA-I in each sample. PBS alone in the apical compartment was used as a control (—). (B) EP values of Aβ in the
presence of spherical apoA-I-HDL, apoA-I-HDL plasma pool or discoidal apoA-I-HDL. PBS alone in the apical compartment was used as a control (—). Data were
expressed as endothelial permeability (EP), reported as the mean ± SEM of triplicate experiments. One-way ANOVA found significant differences (A) F(3,32) = 87.47;
p = 0.00001; (B) F(3,32) = 120.61; p = 0.00001. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.01 by Tukey’s post hoc test.
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In vitro BBB Crossing of apoA-I-HDL
Different subclasses of apoA-I-HDL were added to the apical
compartment of the transwell system and their EP across the
cell monolayer was estimated by measuring the apoA-I content
in the basolateral compartment by ELISA assay for up to 3 h.
The results (Figure 6) showed that discoidal HDL displayed
higher EP values (with a passage of 1.8 ± 0.6% of apical
apoA-I), compared to spherical ones (p = 0.004), and lipid-free
apoA-I (p = 0.048).
Effect of apoA-I Lipidation on Preformed
Aβ Fibrils
The effect of apoA-I lipidation on the disaggregation of
preformed Aβ fibrils was assessed by AFM and thioflavine T
(ThT) assay (Quan et al., 2016). Aβ fibrils were incubated with
apoA-I in different lipidation states for up to 24 h and changes
in the morphology of fibrils were followed by AFM imaging
(Figure 7). The results showed that, starting from mature Aβ
fibrils of comparable length (Figure 7A, row 1), the incubation
with spherical apoA-I HDL did not induce significant changes
in fibril morphology, and concentration (Figure 7A, column 2)
compared to Aβ fibrils alone (Figure 7A, column 1). On the
contrary, incubation with both the apoA-I-HDL plasma pool
(Figure 7, column 3) and discoidal apoA-I-HDL (Figure 7A,
column 4) induced a strong time-dependent reduction of fibril
concentration and extension.
The percentage of pixels above the 1.5 nm threshold
(determined as reported in Supplementary Figure 1) normalized
with respect to the starting point (value at t = 0 h) is reported
for each sample at different times to obtain a quantitative
analysis of AFM images. The results (Figure 7B) demonstrate
the superior capability (1.6-fold increase) of discoidal apoA-
I-HDL in disassembling preformed Aβ fibrils compared to
spherical apoA-I-HDL.
The β-sheet content of Aβ fibril samples were analyzed using
a ThT fluorescence assay and the results (Figure 7C) showed
that when fibrils are in incubation alone or with spherical apoA-
I-HDL, their β-sheet content did not significantly change. On
the contrary, the presence of apoA-I-HDL plasma pool induced
a 40% reduction in β-sheet content after 18 h, and there is an
almost complete disruption of β-sheet structures within 4 h in
the presence of discoidal apoA-I-HDL.
Discoidal apoA-I-HDL Induce a
Structural Destabilization of Aβ
The interaction between discoidal apoA-I-HDL and Aβ17−42 was
evaluated using MD simulations. Protein structural stability was
analyzed by monitoring the time evolution of the root mean
square deviation (RMSD) of Aβ17−42 in water and Aβ17−42 in
complex with apoA-I. Three different replicas of the Aβ17−42
alone in water and in complex with apoA-I were examined to
increase the statistics of the MD data. It was observed that
protein conformational stability was reasonably reached in the
last 20 ns of the simulations (Supplementary Figure 3). The
apoA-I-Aβ17−42 contact surface, characterized by protein-lipid
(Aβ-1,2-dimyristoyl-sn-glycero-3-phosphocholine) and protein-
protein (Aβ-apoA-I) interactions, covers 6.3 ± 2 nm2 of
solvent accessible surface. The hydrophobic interaction plays
a pivotal role in the contact area (Supplementary Figure 4).
The visual inspection of the apoA-I-Aβ17−42 complex through
the MD simulation is reported in Figure 8A and highlights
the conformational destabilization of the Aβ17−42 due to the
interaction with apoA-I.
The previously highlighted conformational instability can be
quantified by analyzing the fibril order parameter (ordP), as
reported in Figure 8B. A significantly decreased ordP value
(ordP < 1 are typical of a distorted structure) was found in
the case of apoA-I-Aβ17−42 (ordP = 0.60 ± 0.02) compared
FIGURE 6 | In vitro BBB crossing of different subclasses of human plasma HDL. The passage of apoA-I in different lipidation states (spherical apoA-I-HDL, discoidal
apoA-I-HDL, apoA-I-HDL plasma pool, or lipid-free apoA-I) across the hCMEC/D3 monolayer was determined by measuring apoA-I in the lower compartment of the
transwell system at different incubation times (up to 3 h) by ELISA assay. Data were expressed as endothelial permeability (EP), reported as the mean ± SEM of
triplicate experiments. One-way ANOVA found a significant difference [F(3,32) = 75.14; p = 0.00001]. ∗∗p < 0.01, ∗∗∗p < 0.01 by Tukey’s post hoc test.
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FIGURE 7 | Disaggregation of preformed Aβ fibrils in the presence of HDL. (A) Representative AFM images of Aβ fibrils over time, incubated at 37◦C either alone
(column 1) or with different HDL subclasses: spherical HDL (column 2), total HDL plasma pool (column 3), discoidal HDL (column 4). Images are 4 µm2 × 4 µm2,
1024 × 1024-pixel, Z-scale 10 nm. (B) The normalized percentage of pixels with a height above a threshold of 1.5 nm (white pixel percentage) is reported for Aβ in
the presence of the different HDL subclasses at different incubation times. Values are the average of pixels higher than the threshold over several images acquired on
the same sample. Error bars represent SD Each sample is normalized to its respective starting point (value at t = 0 h). (C) Thioflavine T fluorescence as a function of
time in samples containing 2 µM Aβ fibrils alone (blue dotted) or incubated with spherical HDL (green dotted), total HDL pool (orange dotted), or discoidal HDL
(purple dotted). The intensities were normalized to the respective zero-time intensity.
to Aβ17−42 alone in water (ordP = 0.79 ± 0.02). The PCA
provides another image, which highlights the large-scale and
low frequency modes mainly related to the distortion of the
Aβ fibril. After the alignment of the Aβ C-α atoms, the
covariance matrix was calculated, and diagonalized for each
simulated system (Aβ17−42 in water and Aβ17−42 in complex
with apoA-I). The amplitude of the first Principal Component
Vector, which takes into account more than 50% of the total
variance of the protein motion, is reported in Figure 8C,
highlighting a marked increase of conformational fluctuations
when Aβ17−42 is in complex with apoA-I (eigvalPCA1 = 17)
compared to Aβ17−42 alone in water (eigvalPCA1 = 5). Finally,
a decreased β-sheet content was observed by computing the
secondary structures probabilities (Figure 8D) along the Aβ
fibril chains at the equilibrium, as previously described (Deriu
et al., 2014, 2016b; Grasso et al., 2015, 2016, 2017; Janaszewska
et al., 2017). Despite the beta-sheet percentage decreases only by
14%, this is a statistically significant molecular event observed
only in the apoAI-Aβ molecular system in the simulated time-
scale of 100 ns. Moreover, the marked loss of structural order,
quantified by fibril order parameter, will further affect the beta-
sheet percentage in longer time-scale. Within this framework, our
results clearly show a molecular event not observed in the Aβ
system in water environment, i.e., the ability of apoA-I protein
to affect the conformational stability of Aβ in the investigated
time-scale of 100 ns.
We note that, notwithstanding the different experimental
and simulative approaches, the ThT and simulation techniques
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FIGURE 8 | Molecular dynamic simulation analysis. (A) Visual inspection of the apoA-I interaction with Aβ fibril at the beginning (t = 0 ns) and at the end (t = 100 ns)
of the MD simulation. The side-view and top-view representations are reported in the upper and lower panels, respectively. Yellow represents Aβ17-42 and magenta
represents apoA-I. (B–D) The destabilization of Aβ fibril by discoidal apoA-I-HDL obtained by MD simulations is shown. (B) the order parameter calculated at the
equilibrium, (C) the eigenvalue of the first PCA vector, and (D) the β-sheet content of Aβ fibril alone in water and in complex with apoA-I.
both suggest a relevant role in Aβ destabilization induced
by discoidal HDL.
DISCUSSION
Considerable evidence suggests that plasma HDL, as well as
having vasoprotective functions, could exert a protective role
in AD (Kingwell et al., 2014; Vitali et al., 2014), and but the
mechanisms involved have not been thoroughly investigated.
Since Aβ clearance from the brain, a way to counteract
the onset or progression of AD, partially occurs across the
brain vasculature (Bates et al., 2009), and it is essential to
understand if and how circulating HDL might affect Aβ
passage across the BBB.
Considering previously published data about the ability of
HDL and apoA-I to bind Aβ in vitro (Koldamova et al., 2001;
Paula-Lima et al., 2009; Shih et al., 2014) and reduce Aβ levels
in the brain of AD animal models (Robert et al., 2016), we
hypothesized that plasma-derived HDL acts by accelerating the
Aβ egress from the brain to the blood via “sink effect,” as
already speculated for different Aβ binding molecules or particles
(Golabek et al., 1995; Mancini et al., 2016).
To investigate this issue, we used a simple BBB model
consisting of an hCMEC/D3 monolayer that separates a
basolateral compartment containing Aβ fibrils to mimic the
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AD brain from an apical one containing different human
HDL subclasses, and mimicking the blood. We chose to carry
out the experiments on fibrils, since we have already shown,
using the same BBB model system utilized in the present
investigation, that oligomers are able to exit from the brain side
either spontaneously or by “sink effect” induced by Aβ-binding
liposomes (Mancini et al., 2016).
The results showed that the presence of apoA-I in the apical
compartment of the transwell system strongly enhanced the Aβ
egress from the basolateral one. This effect is dependent on the
lipidation of apoA-I, reaching the maximum Aβ eﬄux when
apoA-I is folded in discoidal HDL. Actually, no effect on Aβ eﬄux
was detected when apoA-I was contained in mature spherical
HDL. It should be noted that other lipid-based nanoparticles
functionalized with Aβ ligands (Mancini et al., 2016) showed the
ability to promote Aβ clearance, however with a lower efficiency
compared to discoidal HDL.
Our results suggest the possibility that the apoA-I
conformation, which depends on its lipidation state, may
be also involved. In fact, the flexible apoA-I molecule adapts
its structural motif to stabilize the different HDL subclasses
(Silva et al., 2008; Phillips, 2013).
Therefore, we theorize that the plasma profile of HDL
subclasses could differ between healthy and AD patients, thus
affecting Aβ clearance from the brain. A recent study showed that
HDL from AD patients were less functional compared to HDL
from healthy subjects (Camponova et al., 2017), supporting this
idea. Since only small soluble Aβ assemblies, and not fibrils, are
able to cross the endothelial monolayer (Mancini et al., 2016),
and since apoA-I is not synthetized in the brain (Demeester et al.,
2000; Koch et al., 2001), the herein shown ability of apoA-I-HDL
to promote the Aβ clearance across the BBB should assume their
ability to cross the barrier and to disaggregate fibrils.
To verify this speculation, we tested the ability of HDL
subclasses to cross the BBB in vitro.
Our results show that when apoA-I folded its structure in
discoidal HDL, rather than in spherical particles, it was able
to cross the BBB in vitro, suggesting that the lipidation state
of apoA-I could be a key determinant affecting these features.
Moreover, we found that the apical/basolateral ratio of apoA-
I in our model system is comparable with the plasma/CSF
ratio. Concerning the mechanism of apoA-I crossing, it should
be noted that previous work suggests that the SR-BI receptor
is highly selective for lipid uptake, and excludes apoAI and
apoAII (Acton et al., 1996; Gillard et al., 2017). Therefore,
our speculation is that apoA-I crosses the BBB through a
mechanism involving the LDL receptor-related protein family,
as previously suggested (Merino-Zamorano et al., 2016), and
that the shape and size of HDL could be additional determining
factors (Fernández-de-Retana et al., 2017).
To the best of our knowledge, the data about the ability
of different HDL subclasses to cross the BBB reported in this
investigation have never been published before.
Finally, we investigated the effect of different apoA-I-HDL
subclasses on pre-formed Aβ fibrils by AFM imaging, ThT assay,
and MD simulation. AFM imaging showed that the presence
of discoidal apoA-I-HDL strongly reduced the amount and
concentration of long fibrils. This was confirmed by ThT assay,
where a strong, and rapid reduction of the β-sheet content of
fibrils was detected. The molecular modeling results highlighted
the conformational destabilization of Aβ upon its interaction
with apoA-I when associated to discoidal HDL. A significant
distortion of the fibril order and a decrease in the β-sheet content
was identified, clearly suggesting a key role played by discoidal
apoA-I-HDL in destabilizing the Aβ fibrils.
Taken all together the data reported in present investigation,
suggest that apoA-I-HDL action is not only peripheral via “sink
effect,” but also central after BBB crossing.
In summary, we can speculate that at earliest stages of AD,
discoidal apoA-I-HDL species in plasma, more than alternatively
lipidated HDL species, may be involved in synergic activity
with brain discoidal apoA-I-HDL pool: the central HDL pool
maintains Aβ in a soluble form, while the peripheral HDL
pool enhances its eﬄux from the brain. These results add
new information to previously published knowledge (Robert
et al., 2016, 2017b; Slot et al., 2017), suggesting that the
lipidation state of apoA-I, and its conformation may be an
important determinant for its role in preventing β-amyloidosis,
and therefore may influence the pathogenesis of AD.
Our results are also in agreement with a previously published
study about the ability of apoA-I-HDL to promote clearance of
Aβ through the cerebral vessel (Robert et al., 2017b) in a more
advanced 3D cerebrovascular model. Our data adds new insights
about the potential ability of discoidal HDL to cross the BBB and
to destroy Aβ aggregates enhancing its clearance from the brain.
Considering that the main brain apoprotein, apoE, promotes
Aβ aggregation (Dafnis et al., 2016), we can speculate
that the ratio with brain apoA-I, promoting disaggregation,
may be an important key point in modulating the peptide
aggregation/disaggregation paradigm. Moreover, considering
that apoE in the blood is able to promote Aβ clearance from the
brain (Robert et al., 2017b) its coupling with the disaggregating
activity of brain apoA-I could play an important role in brain
Aβ clearance. Finally, considering that Aβ cleared into the blood
interacts with circulating apoA-I, preventing its aggregation
and reducing its accumulation in the vasculature (Handattu
et al., 2009; Lefterov et al., 2010; Lewis et al., 2010; Robert
et al., 2016, 2017a; Fernández-de-Retana et al., 2017) depicts
a complex interplay among these apolipoproteins in the brain
and in the blood.
However, the synergic action between different lipoproteins in
modulating Aβ aggregation/disaggregation and transport across
the BBB will be an important issue to be investigated.
As a final consideration, it should be pointed out that
the results herein reported have been obtained using an
in vitro model. Evidently, the neurovascular unit (NVU), the
area where these processes naturally occur, is considerably
more complex than endothelial cells alone (Sagare et al.,
2012). Indeed, the brain capillary endothelial cells of the
BBB do not function alone, but they work in synergy within
a context of a multicellular NVU, which includes neurons,
astrocytes, pericytes, and microglia and the blood vessels
themselves (McConnell et al., 2017). The NVU components
cooperate to regulate cerebrovascular function and permeability
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through the vasculature, which has unique structure along the
vascular tree in the brain (Andreone et al., 2017). Thus, different
structures can contribute to Aβ exchange across the BBB.
Accordingly, our results should be taken as an indication that will
deserve confirmation on a model closer to the physiological state
(Robert et al., 2017a) or in vivo in animal models.
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